You are Invited to Attend:
Personalized Medicine for Neuropsychiatric Disorders
AN ASSUREX HEALTH PRESENTATION
CLINICAL APPLICATIONS OF PSYCHIATRIC PHARMACOGENOMICS
Wednesday, September 21, 2016
Michael V. Genovese, MD, JD
Chief Medical Oﬃcer,
Sierra Tucson, Acadia Healthcare
Fleming's Prime Steakhouse & Wine Bar
6360 N. Campbell Avenue
Tucson, AZ 85718
Dinner will be provided.
About the Presenter:
Michael Genovese is the Chief Medical Oﬃcer of Sierra Tucson, a world leader in integrative health.
He is Assistant Clinical Professor of Medicine at the University of Arizona, a Diplomate of the American Board of Psychiatry and Neurology, and a member of the American Psychiatric Association and of the American Academy of Addiction Psychiatry. Before joining Sierra Tucson, Dr. Genovese co-founded Long Island Mind and Body (LIMB), a medical practice that brought state-of-the-art integrative treatments to a growing patient-base in metropolitan New York. While establishing LIMB he also practiced as an attending physician at nearby Winthrop University Hospital. He was a fellow at the New York University/North Shore University Hospital Child and Adolescent Psychiatry Program, and he completed his residency training at the University of Connecticut School of Medicine. Before beginning his medical studies, Dr. Genovese earned a Juris Doctor degree at the University of Pittsburgh School of Law. Dr. Genovese writes, speaks, teaches and consults widely in the disciplines of pharmacology, neuromodulation and pharmacogenomics.
About the Sponsor:
GeneSight® is a combinatorial pharmacogenomic test clinically proven to improve medication selection for patients that are aﬀected by neuropsychiatric conditions including depression, posttraumatic stress disorder (PTSD), anxiety, bipolar disorder, schizophrenia, acute and chronic pain, ADHD and other behavioral health conditions. Powered by CPGx™ , a proprietary combinatorial pharmacogenomics technology, GeneSight measures multiple genomic variants for each patient and weights them together – rather than one at a time – to provide comprehensive genetically driven recommendations for each medication for each patient on an actionable, easy to interpret report. Multiple clinical studies have demonstrated that when GeneSight guided patients’ treatment, they were more than twice as likely to respond to selected medications and experienced double the likelihood of remission from their illness compared to current standard of care.1,2 GeneSight was developed in the Assurex Health clinical laboratory based on patented technology from Mayo Clinic and Cincinnati Children’s Hospital Medical Center, who continue to be research collaborators. In clinical use for over 6 years, GeneSight has more than 15,000 registered healthcare providers, and more than 250,000 patients have undergone GeneSight testing.
©2016 Assurex Health, Inc.
6030 S. Mason-Montgomery Road
Mason, OH 45040
Assurex and GeneSight are trademarks of Assurex Health, Inc. All rights reserved. Printed in the U.S.A.
1. Hall-Flavin DK, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogen- et Genomics. 2013 Oct;23(10):535-48.
2. Winner JG, et al. A prospective, randomized double-blind study assessing.